NOTIFICATION ON ENABLING AND SCIENTIFICALLY PROVING REJUVENATIVE EFFECT WITH HEALTH FOOD (NMN SUPPLEMENTS) SHINKOWA PHARMACEUTICAL ANNOUNCES ACQUISITION OF ALL SHARES OF HAKUSHINDO PHARMACEUTICAL

Toward the Realization of Academic-industry Integration for True Anti-aging Medicine (Rejuvenation Research) TOKYO, June 19 (Bernama-BUSINESS WIRE) -- Shinkowa Pharmaceutical Co., Ltd., (Head Office: Chuo-ku, Tokyo, CEO: Megumi Tanaka), a company striving to achieve rejuvenation with health food and conducting clinical studies to scientifically confirm the effect, has acquired all shares of Hakushindo Pharmaceutical Co., Ltd. (head office: Shinjuku-ku, Tokyo), an organization that provides research funds to the Project Research Center For Clinical Trials and Preventative Medicine at the Hiroshima University Graduate School of Biomedical & Health Sciences, the organization that has carried out the world's first clinical study of the long-term oral intake (24 weeks) of β nicotinamide mononucleotide (NMN). (Growth hormone increase observed, mitochondrial activity observed, Sirtuin gene expression being assessed)   This press release features multimedia. View the full release here:https://www.businesswire.com/news/home/20180618005415/en/ Clinical studies on oral NMN intake are currently underway at Hiroshima University Graduate School of Biomedical & Health Sciences: Project Research Center For Clinical Trials and Preventative Medicine. (However, there are no plans for public disclosure of the clinical research results.) UMIN trial ID: UMIN000025739 http://rctportal.niph.go.jp/en/detail?trial_id=UMIN000025739 Based on the results of these clinical studies at Hiroshima University Graduate School of Biomedical & Health Sciences: Project Research Center For Clinical Trials and Preventative Medicine, Shinkowa Pharmaceutical intends to develop products based on the newly discovered effects of NMN, and to continue clinical researches in fields where potential effect is demonstrated. Although we do not plan to publicly announce the results of this clinical study, we do intend to actively disclose the information free of charge to researchers and organizations involved in NMN research. http://mrem.bernama.com/viewsm.php?idm=32122